Hematologic Malignancy
Follicular Lymphoma
CI-CAN-00005316Explore in graph →
Hematologic216 active trials8 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005316Explore in graph →
Rankings
12 current ranking rows (latest year per scope). Each row lists the scope, the formula version, the value and the exact inputs that produced it.
| Metric | Scope | Rank / eligible | Δ | Value | Percentile | Confidence | Formula | Generated | Inputs |
|---|---|---|---|---|---|---|---|---|---|
| Curated clinical evidence items | World · both sexes · all ages · latest · all malignant entities | #187 / 492 | = | 12 count | 62.1 | Medium confidence | ci-civic-evidence-v1 | Sep 29, 2026 | showformula: COUNT(civic_evidence_items) WHERE status = ACCEPTED AND cancer_id IN descendants(cancer)
inputs hash 00ec4259c26ee135c931f5a6 Trace lineage (admin) |
| Genes with curated or cohort evidence | World · both sexes · all ages · latest · all malignant entities | #302 / 521 | = | 3 count | 42.1 | Medium confidence | ci-genes-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT gene) FROM (civic accepted evidence ∪ gdc frequency ≥ 0.05 AND cases_affected ≥ 20)
inputs hash dc02edfbbd5b601934401df4 Trace lineage (admin) |
| Publications, last 12 months | World · both sexes · all ages · latest · all malignant entities | #230 / 2,294 | = | 203 count | 90 | Medium confidence | ci-pubs-12m-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 12m
inputs hash 6636ad9f834652e029647409 Trace lineage (admin) |
| Publications, last 5 years | World · both sexes · all ages · latest · all malignant entities | #203 / 2,873 | = | 1,390 count | 93 | Medium confidence | ci-pubs-5y-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 5y (query stored per row)
inputs hash 531d42217f151c0dd79899a6 Trace lineage (admin) |
| Publication growth | World · both sexes · all ages · latest · all malignant entities | #239 / 286 | = | 0.78 ratio | 16.5 | Medium confidence | ci-pub-growth-v1 | Sep 29, 2026 | showformula: publications_12m / (publications_5y_prior / 5)
inputs hash 3385afecab0ace04e61b6db0 Trace lineage (admin) |
| Trial registration growth (year over year) | World · both sexes · all ages · latest · all malignant entities | #159 / 186 | = | -0.09 ratio | 14.6 | Medium confidence | ci-trial-growth-v1 | Sep 29, 2026 | showformula: (new_trials_12m − new_trials_prior_12m) / new_trials_prior_12m (first_posted_date windows; interventional; descendants)
|
| Active clinical trials | World · both sexes · all ages · latest · all malignant entities | #136 / 1,654 | = | 216 count | 91.8 | Medium confidence | ci-active-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING)
inputs hash f2f5ed2084d93bba6dcb810e Trace lineage (admin) |
| Active Phase III trials | World · both sexes · all ages · latest · all malignant entities | #127 / 810 | = | 26 count | 84.4 | Medium confidence | ci-phase3-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … active statuses AND PHASE3 = ANY(phases)
inputs hash 56fba75197c8c0044b9e345f Trace lineage (admin) |
| Recruiting clinical trials | World · both sexes · all ages · latest · all malignant entities | #142 / 1,277 | = | 107 count | 88.9 | Medium confidence | ci-recruiting-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL
inputs hash 4352f89d0670b61272a585b3 Trace lineage (admin) |
| Recruiting Phase III trials | World · both sexes · all ages · latest · all malignant entities | #143 / 585 | = | 10 count | 75.7 | High confidence | ci-phase3-recruiting-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND PHASE3 = ANY(phases) AND study_type = INTERVENTIONAL
inputs hash ada23aaf0a7d803bc6e67424 Trace lineage (admin) |
| Sponsor concentration (HHI) | World · both sexes · all ages · latest · all malignant entities | #513 / 615 | = | 0.014 index (0–1) | 16.6 | High confidence | ci-sponsor-hhi-v1 | Sep 29, 2026 | showformula: Σ (active_trials_by_lead_sponsor / active_trials)² over the cancer and its descendants
|
| Trial termination share | World · both sexes · all ages · latest · all malignant entities | #95 / 454 | = | 0.39 ratio | 79.2 | High confidence | ci-trial-termination-v1 | Sep 29, 2026 | showformula: (terminated + withdrawn) / (completed + terminated + withdrawn) WHERE first_posted_date ≥ 2010-01-01 AND study_type = INTERVENTIONAL
|
Computed Ranks are competition ranks (ties share a rank). Percentile = share of eligible entities ranked at or below this one in the ranking direction.
"Deadliest" is ambiguous: annual deaths, age-standardized mortality rate, mortality-to-incidence ratio and 5-year survival rank cancers differently. CancerIndex publishes each as a separate metric.
inputs hash f271e5ec1a95b0a8843d9337
inputs hash d0a365cf448b4492e5842c02
inputs hash b91f4c1d0fc49c7e7afbbdb1
Unmet need · computed
No research-gap components for this entity